2015
Ovarian cancer survival by tumor dominance, a surrogate for site of origin
Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes & Control 2015, 26: 601-608. PMID: 25771796, PMCID: PMC4561551, DOI: 10.1007/s10552-015-0547-y.Peer-Reviewed Original ResearchConceptsDominant tumorHazard ratioFallopian tubeEstrogen hormone replacement therapyConclusionThese preliminary findingsHormone replacement therapyDistal fallopian tubeRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsProportional hazards modelSite of originTubal originWorse survivalReplacement therapyOvarian tumorsCancer survivalOvarian cancerPathology reportsOnly subtypeBRCA1/2 mutationsHazards modelObjectivesRecent studiesTumors
2003
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes & Control 2003, 14: 439-446. PMID: 12946038, DOI: 10.1023/a:1024932427503.Peer-Reviewed Original ResearchConceptsBRCA1 carriersOC useTubal ligationOvarian cancerReproductive factorsInvasive epithelial ovarian cancerFounder mutationOral contraceptive useHistory of breastfeedingEpithelial ovarian cancerOvarian cancer casesOvarian cancer riskBRCA1 founder mutationsBRCA2 mutation carriersAshkenazi founder mutationsCase-only studyNulliparous womenGynecologic surgeryBRCA1/2 carriersRisk factorsBRCA2 mutationsCancer casesLive birthsBRCA1/2 mutationsContraceptive use